EDAP TMS at Jefferies Conference: Strategic Shift to HIFU Therapy

EDAP TMS SA (EDAP) presented at the Jefferies Global Healthcare Conference, detailing a strategic shift to focus entirely on High-Intensity Focused Ultrasound (HIFU) therapy, particularly for prostate cancer treatment, while phasing out its legacy kidney stone business. The company highlighted positive reimbursement trends, including a 90% increase in CMS category six reimbursement in 2023 and an additional 5% in January 2025, alongside favorable CPT code adjustments for physicians. EDAP is also expanding HIFU applications to include BPH and endometriosis, with ongoing clinical studies and a recent CE Mark for endometriosis treatment, though the company is monitoring potential tariff impacts of 10% on goods entering the U.S.

Analysis

EDAP TMS SA (NASDAQ:EDAP) is undergoing a significant strategic transformation, concentrating its efforts exclusively on High-Intensity Focused Ultrasound (HIFU) therapy and divesting its legacy kidney stone treatment business. This pivot targets the substantial and growing prostate cancer market, where HIFU is gaining traction over traditional treatments like surgery and radiation, as evidenced by CMS data from 2022-2023 showing declines in the latter. The company recently launched its advanced Focal One I platform, featuring HiFusion technology and remote treatment capabilities, which has been well-received. EDAP's market position is reinforced by strong clinical data, notably from the French government-funded HiFi study (published December 2024) and the FARP randomized controlled trial (presented at AUA in May/April 2025), both demonstrating HIFU's comparable oncologic efficacy to surgery with superior functional outcomes for patients. This robust clinical evidence is anticipated to support potential changes in treatment guidelines. Financially, EDAP benefits from a favorable reimbursement environment, with CMS Category six payments increasing 90% in 2023 and a further 5% in January 2025, and CPT code 55880 awarding physicians 17.73 work RVUs. The company has achieved significant market penetration, with installations in 7 of the top 10 U.S. News & World Report ranked hospitals and 48% of national comprehensive cancer network hospitals, leveraging a successful model from the New York/New Jersey market. Future growth is also anticipated from new HIFU indications, including Benign Prostatic Hyperplasia (BPH), with ongoing Phase 1/2 studies, and endometriosis, for which it received CE Mark approval in March 2025 and has initiated a limited launch in Europe. While the outlook is largely positive, the company is monitoring a potential 10% tariff impact on goods imported into the US from its French manufacturing facilities.

Key Decisions for Investors

• Investors should evaluate EDAP's execution on its focused HIFU strategy, considering the strong clinical validation and positive reimbursement trends as key drivers for market share capture in prostate cancer.
• Monitor the commercial uptake of the new Focal One I platform and the progress of clinical studies and market development for new indications such as BPH and endometriosis, as these represent significant future growth catalysts.
• Assess the potential impact of the planned 10% US tariff on the company's cost structure and profitability, and its ability to sustain growth momentum despite this headwind.
• Closely watch for the full publication of the FARP study data and any subsequent revisions to medical guidelines, as these could significantly accelerate HIFU adoption and further solidify EDAP's competitive positioning.